Volume 22, Issue 3 (8-2019)                   J Arak Uni Med Sci 2019, 22(3): 45-58 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khoshchehreh R, Totonchi M, Baharvand H, Ebrahimi M. Investigation the Ability to Produce Induced Pluripotent Cells from Human Pancreatic Cancer Xenografts. J Arak Uni Med Sci 2019; 22 (3) :45-58
URL: http://jams.arakmu.ac.ir/article-1-5973-en.html
1- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Jahad Daneshgahi Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Department of Genetics, Reproductive Medicine Research Center, Jahad Daneshgahi Institute for Reproductive Biology and Medical Sciences, ACECR, Tehran, Iran.
2- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Jahad Daneshgahi Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
3- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Jahad Daneshgahi Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. , mebrahimi@royaninstitute.org
Abstract:   (2518 Views)
Background and Aim: There is increasing evidence that cancer cells in addition to multiple genetic mutations, also acquire epigenetic abnormalities during development, maintenance, and progression. By utilizing the reprogramming technology as a tool to introduce the ‘pressure’ to alter epigenetic regulations, we might be able to clarify the epigenetic behavior that is unique to cancer cells. So far, iPSCs have been generated from normal primary cells, but it is unclear whether human primary cancer cell can be reprogrammed. We investigated the production of the iPS cells from the pancreatic adenocarcinoma cells using defined transcription factors.
Materials and Methods: We sought to reprogram patient derived xenograft from human PDAC, by introducing lentiviral mediated induction of Yamanaka Factors (OSKM) and characterized of induced cells by Alkaline Phosphatase staining, Real-Time PCR and immunostaining.
Ethical Considerations: This study with research ethics code EC/93/1025 has been approved by research ethics committee at Royan Institute.
Findings: Alkaline Phosphatase staining, Real-Time PCR and immunostaining showed that induction with the OSKM results in generating iPS cell line from fibroblast cells but not from PDAC PDX cells .We showed that, PDAC cells could not fully reprogrammed by the expression of 4 transcription factors.
Conclusion: This study demonstrated that the PDAC-PDX cancer cells were distinct from PDAC induced cells with regard to their epigenetic modifier genes expression pattern, although the expression of pluripotency genes did not increased significantly in the induced PDAC cells.
Full-Text [PDF 1167 kb]   (1040 Downloads)    
Type of Study: Original Atricle | Subject: Basic Sciences
Received: 2018/12/20 | Accepted: 2019/01/26

1. Hermann, P.C., S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, M. Guba, et al., Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1(3): 313-23.
2. Zagorac, S., S. Alcala, G. Fernandez Bayon, T. Bou Kheir, M. Schoenhals, A. Gonzalez-Neira, et al., DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. Cancer Res. 2016; 76(15): 4546-58.
3. Jemal, A., R.L. Siegel, J. Ma, F. Islami, C. DeSantis, A. Goding Sauer, et al., Inequalities in premature death from colorectal cancer by state. J Clin Oncol. 2015; 33(8): 829-35.
4. Siegel, D.A., J. King, E. Tai, N. Buchanan, U.A. Ajani and J. Li, Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics. 2014; 134(4): e945-55.
5. Sadikovic, B., K. Al-Romaih, J.A. Squire and M. Zielenska, Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2008; 9(6): 394-408.
6. Yamada, Y., H. Haga and Y. Yamada, Concise review: dedifferentiation meets cancer development: proof of concept for epigenetic cancer. Stem Cells Transl Med. 2014; 3(10): 1182-7.
7. Feinberg, A.P. and B. Tycko, The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2): 143-53.
8. Jones, P.A. and S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6): 415-28.
9. Linhart, H.G., H. Lin, Y. Yamada, E. Moran, E.J. Steine, S. Gokhale, et al., Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 2007; 21(23): 3110-22.
10. Gurdon, J.B., The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol. 1962; 10: 622-40.
11. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. cell. 2007; 131(5):861-72.
12. Lin, S.L., D.C. Chang, S. Chang-Lin, C.H. Lin, D.T. Wu, D.T. Chen, et al., Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008; 14(10): 2115-24.
13. Utikal, J., N. Maherali, W. Kulalert and K. Hochedlinger, Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009; 122(Pt 19): 3502-10.
14. Miyoshi, N., H. Ishii, K. Nagai, H. Hoshino, K. Mimori, F. Tanaka, et al., Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2010; 107(1): 40-5.
15. Zhang, X., F.D. Cruz, M. Terry, F. Remotti and I. Matushansky, Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 2013; 32(18): 2249-60, 2260 e1-21.
16. Kim, J. and K.S. Zaret, Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J. 2015; 34(6): 739-47.
17. Kim, J., J.P. Hoffman, R.K. Alpaugh, A.D. Rhim, M. Reichert, B.Z. Stanger, et al., An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 2013; 3(6): 2088-99.
18. Semi, K. and Y. Yamada, Induced pluripotent stem cell technology for dissecting the cancer epigenome. Cancer Sci. 2015; 106(10): 1251-6.
19. Schlaeger, T.M., L. Daheron, T.R. Brickler, S. Entwisle, K. Chan, A. Cianci, et al., A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015; 33(1): 58-63.
20. Duan, H., Z. Yan, W. Chen, Y. Wu, J. Han, H. Guo, et al., TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2. Gynecol Oncol. 2017; 147(2): 408-417.
21. De Bonis, M.L., S. Ortega and M.A. Blasco, SIRT1 is necessary for proficient telomere elongation and genomic stability of induced pluripotent stem cells. Stem Cell Reports. 2014; 2(5): 690-706.
22. Chen, C.W., R.P. Koche, A.U. Sinha, A.J. Deshpande, N. Zhu, R. Eng, et al., DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015; 21(4): 335-43.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb